Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etacalin hydrochloride tablets in pulmonary arterial hypertension
CTR20132298Phase 2Suspended
- Sponsor
- Beijing Enhua Pharmaceutical Research Institute
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of etacalin in pulmonary arterial hypertension (PAH), Plexogenic Pulmonary Arteriopathy, Scleroderma-associated pulmonary arterial hypertension (SSc-PAH), Heritable Pulmonary Arterial Hypertension (HPAH), sponsored by Beijing Enhua Pharmaceutical Research Institute. Started Jan 2015; status: suspended.
02
Drugs
etacalin
03
Conditions
pulmonary arterial hypertension (PAH)Plexogenic Pulmonary ArteriopathyScleroderma-associated pulmonary arterial hypertension (SSc-PAH)Heritable Pulmonary Arterial Hypertension (HPAH)
Beyond the preview
Go deeper on CTR20132298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132298.